Skip to content

Released Nov 14, 2018, after the close

10-Q filed Nov 14, 2018, 45 days after period end · 0001390478-18-000035

Q3 2018 · 10-Q
Revenue—
Net Income-$290.00KN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$26.75N/M vs Q3 2017N/M vs Q2 2018
Operating Cash Flowderived-$14,165,000N/M

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017Q3 2016Q3 2013
Revenue———$2.17M
Net Income-$290.00K-$4.46M-$6.93M-$6.93M
EPS Diluted-$26.75-$2.27—-$0.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR